Review



cell cycle staining kit  (Multi Sciences (Lianke) Biotech Co Ltd)


Bioz Verified Symbol Multi Sciences (Lianke) Biotech Co Ltd is a verified supplier
Bioz Manufacturer Symbol Multi Sciences (Lianke) Biotech Co Ltd manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 98

    Structured Review

    Multi Sciences (Lianke) Biotech Co Ltd cell cycle staining kit
    Cell Cycle Staining Kit, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 98/100, based on 1417 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell cycle staining kit/product/Multi Sciences (Lianke) Biotech Co Ltd
    Average 98 stars, based on 1417 article reviews
    cell cycle staining kit - by Bioz Stars, 2026-05
    98/100 stars

    Images



    Similar Products

    98
    Multi Sciences (Lianke) Biotech Co Ltd cell cycle staining kit
    Cell Cycle Staining Kit, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell cycle staining kit/product/Multi Sciences (Lianke) Biotech Co Ltd
    Average 98 stars, based on 1 article reviews
    cell cycle staining kit - by Bioz Stars, 2026-05
    98/100 stars
      Buy from Supplier

    99
    Beyotime apoptosis analysis kit
    Apoptosis Analysis Kit, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apoptosis analysis kit/product/Beyotime
    Average 99 stars, based on 1 article reviews
    apoptosis analysis kit - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    99
    Beyotime cell cycle and apoptosis analysis kit
    Broad-spectrum antitumor activity of B6ADC (A) Tumor suppression efficacy of B6ADC in multiple pancreatic cancer CDX models ( n = 5∼7/group). (B) Tumor suppression efficacy of B6ADC in four cell lines with varying TROP2/c-Met expression levels ( n = 5∼7/group). Scale bar, 50 μm. (C) Tumor suppression effect of a single 2.2 mg/kg dose of B6ADC in SPC-A1 lung adenocarcinoma-bearing mice with a tumor volume of 1,200 mm 3 ( n = 5∼7/group). (D) Comparison of tumor suppression between B6ADC and the combination of parental “TROP2ADC and c-MetADC” in SPC-A1 tumor-bearing mice (initial tumor volume: 600 mm 3 ) ( n = 6/group). See also . (E) Comparison of tumor suppression between B6ADC and the combination of “marketed TROP2ADC (SG) and marketed c-MetADC (Teliso-V)” in SPC-A1 tumor-bearing mice (initial tumor volume: 600 mm 3 ) ( n = 5∼7/group). See also . (F) Transmission electron microscopy images showing <t>apoptosis</t> in BxPC-3 tumors on day 7 after treatment with B6ADC and the control. Apoptotic features (e.g., chromatin condensation and nuclear fragmentation) were observed in the B6ADC-treated group ( n = 3 independent experiments). Scale bar, 2 μm. See also . Statistical analysis was performed using two-way ANOVA. The data are presented as the means ± SDs. ∗ p < 0.05, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001, and p > 0.05 (no significance, ns).
    Cell Cycle And Apoptosis Analysis Kit, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell cycle and apoptosis analysis kit/product/Beyotime
    Average 99 stars, based on 1 article reviews
    cell cycle and apoptosis analysis kit - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    98
    Multi Sciences (Lianke) Biotech Co Ltd cell cycle analysis kit
    <t>Single-cell</t> transcriptomics reveals heterogeneity of the cell <t>cycle</t> dynamics underlying NE lineage plasticity (A and B) UMAP visualization of single-cell transcriptomes from the in-house (A, 64,756 cells) and public (B, 201,720 cells) scRNA-seq cohorts, colored by major cell type annotations. The zoomed views show the UMAP visualizations of epithelial cells, classified into lu/ba, NE-like, and NE subtypes. (C) Dot plot showing the expression patterns of lu/ba, NE-like, and NE signature genes across epithelial cell subtypes from the in-house and public cohorts. (D) KEGG pathway enrichment <t>analysis</t> of DEGs from in-house scRNA-seq cohort, showing the top enriched pathways for NE-like vs. lu/ba epithelial cells and NE vs. lu/ba epithelial cells, with cell cycle-related pathways prominently enriched in both comparisons. (E) NMF-based similarity matrix of integrated epithelial cells from both in-house and public scRNA-seq cohorts was constructed with NE differentiation-associated genes from the MEmidnightblue module were identified via WGCNA. (F) UMAP visualization of epithelial cells from (E) colored by dominant MP assignment. (G) Heatmap showing the observed-to-expected ratio (R o/e) of meta-program-assigned epithelial cells across lu/ba, NE-like, and NE subtypes. (H) Sankey diagram showing the correspondence between NE/NE-like subtype annotations and dominant MP assignments. NE-like cells are predominantly associated with MP1, whereas NE-like cells align with MP2. (I) GSEA plot showing the enrichment scores for the G2/M and G1/S cell cycle phases for the MP1 and MP2 groups. NES, normalized enrichment score. (J) Cell cycle phases of lu/ba, NE-like, and NE epithelial cells from the in-house and public scRNA-seq cohorts.
    Cell Cycle Analysis Kit, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell cycle analysis kit/product/Multi Sciences (Lianke) Biotech Co Ltd
    Average 98 stars, based on 1 article reviews
    cell cycle analysis kit - by Bioz Stars, 2026-05
    98/100 stars
      Buy from Supplier

    99
    Beyotime beyotime cell cycle
    <t>Single-cell</t> transcriptomics reveals heterogeneity of the cell <t>cycle</t> dynamics underlying NE lineage plasticity (A and B) UMAP visualization of single-cell transcriptomes from the in-house (A, 64,756 cells) and public (B, 201,720 cells) scRNA-seq cohorts, colored by major cell type annotations. The zoomed views show the UMAP visualizations of epithelial cells, classified into lu/ba, NE-like, and NE subtypes. (C) Dot plot showing the expression patterns of lu/ba, NE-like, and NE signature genes across epithelial cell subtypes from the in-house and public cohorts. (D) KEGG pathway enrichment <t>analysis</t> of DEGs from in-house scRNA-seq cohort, showing the top enriched pathways for NE-like vs. lu/ba epithelial cells and NE vs. lu/ba epithelial cells, with cell cycle-related pathways prominently enriched in both comparisons. (E) NMF-based similarity matrix of integrated epithelial cells from both in-house and public scRNA-seq cohorts was constructed with NE differentiation-associated genes from the MEmidnightblue module were identified via WGCNA. (F) UMAP visualization of epithelial cells from (E) colored by dominant MP assignment. (G) Heatmap showing the observed-to-expected ratio (R o/e) of meta-program-assigned epithelial cells across lu/ba, NE-like, and NE subtypes. (H) Sankey diagram showing the correspondence between NE/NE-like subtype annotations and dominant MP assignments. NE-like cells are predominantly associated with MP1, whereas NE-like cells align with MP2. (I) GSEA plot showing the enrichment scores for the G2/M and G1/S cell cycle phases for the MP1 and MP2 groups. NES, normalized enrichment score. (J) Cell cycle phases of lu/ba, NE-like, and NE epithelial cells from the in-house and public scRNA-seq cohorts.
    Beyotime Cell Cycle, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/beyotime cell cycle/product/Beyotime
    Average 99 stars, based on 1 article reviews
    beyotime cell cycle - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    Image Search Results


    Broad-spectrum antitumor activity of B6ADC (A) Tumor suppression efficacy of B6ADC in multiple pancreatic cancer CDX models ( n = 5∼7/group). (B) Tumor suppression efficacy of B6ADC in four cell lines with varying TROP2/c-Met expression levels ( n = 5∼7/group). Scale bar, 50 μm. (C) Tumor suppression effect of a single 2.2 mg/kg dose of B6ADC in SPC-A1 lung adenocarcinoma-bearing mice with a tumor volume of 1,200 mm 3 ( n = 5∼7/group). (D) Comparison of tumor suppression between B6ADC and the combination of parental “TROP2ADC and c-MetADC” in SPC-A1 tumor-bearing mice (initial tumor volume: 600 mm 3 ) ( n = 6/group). See also . (E) Comparison of tumor suppression between B6ADC and the combination of “marketed TROP2ADC (SG) and marketed c-MetADC (Teliso-V)” in SPC-A1 tumor-bearing mice (initial tumor volume: 600 mm 3 ) ( n = 5∼7/group). See also . (F) Transmission electron microscopy images showing apoptosis in BxPC-3 tumors on day 7 after treatment with B6ADC and the control. Apoptotic features (e.g., chromatin condensation and nuclear fragmentation) were observed in the B6ADC-treated group ( n = 3 independent experiments). Scale bar, 2 μm. See also . Statistical analysis was performed using two-way ANOVA. The data are presented as the means ± SDs. ∗ p < 0.05, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001, and p > 0.05 (no significance, ns).

    Journal: Cell Reports Medicine

    Article Title: A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer

    doi: 10.1016/j.xcrm.2026.102688

    Figure Lengend Snippet: Broad-spectrum antitumor activity of B6ADC (A) Tumor suppression efficacy of B6ADC in multiple pancreatic cancer CDX models ( n = 5∼7/group). (B) Tumor suppression efficacy of B6ADC in four cell lines with varying TROP2/c-Met expression levels ( n = 5∼7/group). Scale bar, 50 μm. (C) Tumor suppression effect of a single 2.2 mg/kg dose of B6ADC in SPC-A1 lung adenocarcinoma-bearing mice with a tumor volume of 1,200 mm 3 ( n = 5∼7/group). (D) Comparison of tumor suppression between B6ADC and the combination of parental “TROP2ADC and c-MetADC” in SPC-A1 tumor-bearing mice (initial tumor volume: 600 mm 3 ) ( n = 6/group). See also . (E) Comparison of tumor suppression between B6ADC and the combination of “marketed TROP2ADC (SG) and marketed c-MetADC (Teliso-V)” in SPC-A1 tumor-bearing mice (initial tumor volume: 600 mm 3 ) ( n = 5∼7/group). See also . (F) Transmission electron microscopy images showing apoptosis in BxPC-3 tumors on day 7 after treatment with B6ADC and the control. Apoptotic features (e.g., chromatin condensation and nuclear fragmentation) were observed in the B6ADC-treated group ( n = 3 independent experiments). Scale bar, 2 μm. See also . Statistical analysis was performed using two-way ANOVA. The data are presented as the means ± SDs. ∗ p < 0.05, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001, and p > 0.05 (no significance, ns).

    Article Snippet: Cell Cycle and Apoptosis Analysis Kit , BEYOTIME , Cat#C1052.

    Techniques: Activity Assay, Expressing, Comparison, Transmission Assay, Electron Microscopy, Control

    Single-cell transcriptomics reveals heterogeneity of the cell cycle dynamics underlying NE lineage plasticity (A and B) UMAP visualization of single-cell transcriptomes from the in-house (A, 64,756 cells) and public (B, 201,720 cells) scRNA-seq cohorts, colored by major cell type annotations. The zoomed views show the UMAP visualizations of epithelial cells, classified into lu/ba, NE-like, and NE subtypes. (C) Dot plot showing the expression patterns of lu/ba, NE-like, and NE signature genes across epithelial cell subtypes from the in-house and public cohorts. (D) KEGG pathway enrichment analysis of DEGs from in-house scRNA-seq cohort, showing the top enriched pathways for NE-like vs. lu/ba epithelial cells and NE vs. lu/ba epithelial cells, with cell cycle-related pathways prominently enriched in both comparisons. (E) NMF-based similarity matrix of integrated epithelial cells from both in-house and public scRNA-seq cohorts was constructed with NE differentiation-associated genes from the MEmidnightblue module were identified via WGCNA. (F) UMAP visualization of epithelial cells from (E) colored by dominant MP assignment. (G) Heatmap showing the observed-to-expected ratio (R o/e) of meta-program-assigned epithelial cells across lu/ba, NE-like, and NE subtypes. (H) Sankey diagram showing the correspondence between NE/NE-like subtype annotations and dominant MP assignments. NE-like cells are predominantly associated with MP1, whereas NE-like cells align with MP2. (I) GSEA plot showing the enrichment scores for the G2/M and G1/S cell cycle phases for the MP1 and MP2 groups. NES, normalized enrichment score. (J) Cell cycle phases of lu/ba, NE-like, and NE epithelial cells from the in-house and public scRNA-seq cohorts.

    Journal: Cell Reports Medicine

    Article Title: Targeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinoma

    doi: 10.1016/j.xcrm.2026.102712

    Figure Lengend Snippet: Single-cell transcriptomics reveals heterogeneity of the cell cycle dynamics underlying NE lineage plasticity (A and B) UMAP visualization of single-cell transcriptomes from the in-house (A, 64,756 cells) and public (B, 201,720 cells) scRNA-seq cohorts, colored by major cell type annotations. The zoomed views show the UMAP visualizations of epithelial cells, classified into lu/ba, NE-like, and NE subtypes. (C) Dot plot showing the expression patterns of lu/ba, NE-like, and NE signature genes across epithelial cell subtypes from the in-house and public cohorts. (D) KEGG pathway enrichment analysis of DEGs from in-house scRNA-seq cohort, showing the top enriched pathways for NE-like vs. lu/ba epithelial cells and NE vs. lu/ba epithelial cells, with cell cycle-related pathways prominently enriched in both comparisons. (E) NMF-based similarity matrix of integrated epithelial cells from both in-house and public scRNA-seq cohorts was constructed with NE differentiation-associated genes from the MEmidnightblue module were identified via WGCNA. (F) UMAP visualization of epithelial cells from (E) colored by dominant MP assignment. (G) Heatmap showing the observed-to-expected ratio (R o/e) of meta-program-assigned epithelial cells across lu/ba, NE-like, and NE subtypes. (H) Sankey diagram showing the correspondence between NE/NE-like subtype annotations and dominant MP assignments. NE-like cells are predominantly associated with MP1, whereas NE-like cells align with MP2. (I) GSEA plot showing the enrichment scores for the G2/M and G1/S cell cycle phases for the MP1 and MP2 groups. NES, normalized enrichment score. (J) Cell cycle phases of lu/ba, NE-like, and NE epithelial cells from the in-house and public scRNA-seq cohorts.

    Article Snippet: Cell cycle analysis kit , MultiScience , Cat#CCS012.

    Techniques: Single-cell Transcriptomics, Single Cell, Expressing, Construct

    Mapping reveals TPX2 as a representative and functionally relevant driver of NE-like cells (A) Violin plot showing correlations between NE-like cell top markers and the NE-like Sig score across multiple BLCA transcriptomic cohorts. TPX2, highlighted in red, shows the strongest correlation among the markers analyzed. (B and C) Spatial transcriptomic analysis showing the expression of TPX2 and NE-like Sig scores across spatial locations in bladder tumor tissue (B) and their positive correlation (C). R indicates the Spearman correlation coefficient. (D) Representative mIF image of NEBC tissue showing TPX2 (magenta), INSM1 (cyan), and DAPI (blue). The inset highlights TPX2 + (red arrowheads) and INSM1 + (white arrowheads) cells, which demonstrated minimal colocalization. Scale bars, 50 μm. (E and F) Representative mIF images (E) and quantification (F) showing the proportion of TPX2 + panCK + tumor cells across different tumor grades (Tis/Ta/T1: n = 55; T2: n = 46; T3: n = 43; T4: n = 35). Scale bars, 50 μm. (G and H) Flow cytometry (G) and quantification (H) showing the proportions of T24 and UM-UC-3 cells in different cell cycle phases 48 h after transfection with control siRNA or TPX2 siRNA ( n = 3 per group). (I and J) Flow cytometry (I) and quantification (J) showing the proportions of T24 and UM-UC-3 cell lines in different cell cycle phases in the empty vector control and TPX2-oe groups ( n = 3 per group). (K) qPCR analysis was performed to evaluate changes in the expression levels of NE markers following TPX2 knockdown in the T24 cell line. The data are presented as the means ± SDs in (H, J, and K). The box inside violin plot (A) represents the interquartile range (IQR), with the middle line as the median and the hinges corresponding to the 25th and 75th percentiles. p values were determined by one-way ANOVA in (F, H, and K) and by two-tailed unpaired Student’s t test in (J).

    Journal: Cell Reports Medicine

    Article Title: Targeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinoma

    doi: 10.1016/j.xcrm.2026.102712

    Figure Lengend Snippet: Mapping reveals TPX2 as a representative and functionally relevant driver of NE-like cells (A) Violin plot showing correlations between NE-like cell top markers and the NE-like Sig score across multiple BLCA transcriptomic cohorts. TPX2, highlighted in red, shows the strongest correlation among the markers analyzed. (B and C) Spatial transcriptomic analysis showing the expression of TPX2 and NE-like Sig scores across spatial locations in bladder tumor tissue (B) and their positive correlation (C). R indicates the Spearman correlation coefficient. (D) Representative mIF image of NEBC tissue showing TPX2 (magenta), INSM1 (cyan), and DAPI (blue). The inset highlights TPX2 + (red arrowheads) and INSM1 + (white arrowheads) cells, which demonstrated minimal colocalization. Scale bars, 50 μm. (E and F) Representative mIF images (E) and quantification (F) showing the proportion of TPX2 + panCK + tumor cells across different tumor grades (Tis/Ta/T1: n = 55; T2: n = 46; T3: n = 43; T4: n = 35). Scale bars, 50 μm. (G and H) Flow cytometry (G) and quantification (H) showing the proportions of T24 and UM-UC-3 cells in different cell cycle phases 48 h after transfection with control siRNA or TPX2 siRNA ( n = 3 per group). (I and J) Flow cytometry (I) and quantification (J) showing the proportions of T24 and UM-UC-3 cell lines in different cell cycle phases in the empty vector control and TPX2-oe groups ( n = 3 per group). (K) qPCR analysis was performed to evaluate changes in the expression levels of NE markers following TPX2 knockdown in the T24 cell line. The data are presented as the means ± SDs in (H, J, and K). The box inside violin plot (A) represents the interquartile range (IQR), with the middle line as the median and the hinges corresponding to the 25th and 75th percentiles. p values were determined by one-way ANOVA in (F, H, and K) and by two-tailed unpaired Student’s t test in (J).

    Article Snippet: Cell cycle analysis kit , MultiScience , Cat#CCS012.

    Techniques: Expressing, Flow Cytometry, Transfection, Control, Plasmid Preparation, Knockdown, Two Tailed Test